Detalle Publicación

ARTÍCULO
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
Autores: Llopiz, Diana; Ruiz, Marta; Villanueva, Lorea; Iglesias, Tamara; Silva, Leyre; Egea, Josune; Lasarte Sagastibelza, Juan José; Pivette, Perrine; Trochon-Joseph, Véronique; Vasseur, Bérangère ; Dixon, Graham; Sangro Gómez-Acebo, Bruno Carlos; Sarobe Ugarriza, Pablo (Autor de correspondencia)
Título de la revista: CANCER IMMUNOLOGY IMMUNOTHERAPY
ISSN: 0340-7004
Volumen: 68
Número: 3
Páginas: 379 - 393
Fecha de publicación: 2019
Lugar: WOS
Resumen:
Immune checkpoint inhibitors are currently tested in different combinations in patients with advanced hepatocellular carcinoma (HCC). Nivolumab, an anti-PD-1 agent, has gained approval in the second-line setting in the USA. Epigenetic drugs have immune-mediated antitumor effects that may improve the activity of immunotherapy agents. Our aim was to study the therapeutic efficacy of checkpoint inhibitors (anti-CTLA-4 and anti-PD-1 antibodies) in combination with the histone deacetylase inhibitor (HDACi) Belinostat. In a subcutaneous Hepa129 murine HCC model, we demonstrated that Belinostat improves the antitumor activity of anti-CTLA-4 but not of anti-PD-1 therapy. This effect correlated with enhanced IFN-gamma production by antitumor T-cells and a decrease in regulatory T-cells. Moreover, the combination induced early upregulation of PD-L1 on tumor antigen-presenting cells and late expression of PD-1 on tumor-infiltrating effector T-cells, suggesting the suitability of PD-1 blockade. Indeed, Belinostat combined with the simultaneous blockade of CTLA-4 and PD-1 led to complete tumor rejection. These results provide a rationale for testing Belinostat in combination with checkpoint inhibitors to enhance their therapeutic activity in patients with HCC.